HC Wainwright Brokers Lower Earnings Estimates for MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for shares of Monopar Therapeutics in a research report issued on Monday, March 30th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.77) for the quarter, down from their prior forecast of ($0.55). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.53) EPS, FY2027 earnings at ($1.81) EPS, FY2028 earnings at ($0.54) EPS, FY2029 earnings at $1.79 EPS and FY2030 earnings at $4.38 EPS.

MNPR has been the subject of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Morgan Stanley began coverage on shares of Monopar Therapeutics in a report on Friday, January 9th. They set an “overweight” rating and a $115.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and set a $104.00 price objective on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Monopar Therapeutics currently has a consensus rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Trading Up 2.8%

Shares of Monopar Therapeutics stock opened at $54.79 on Wednesday. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The company’s fifty day simple moving average is $58.98 and its 200-day simple moving average is $71.03. The company has a market cap of $366.55 million, a price-to-earnings ratio of -30.10 and a beta of 1.58.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10).

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors have recently bought and sold shares of MNPR. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics in the 3rd quarter valued at $28,000. BNP Paribas Financial Markets raised its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Monopar Therapeutics during the 4th quarter worth about $65,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Monopar Therapeutics during the 4th quarter worth about $86,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares in the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Trending Headlines about Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating and kept a $100 price target on MNPR, signaling continued conviction on the company’s longer‑term upside and likely supporting investor buying interest. Chardan Reaffirms Buy
• Positive Sentiment: HC Wainwright raised several medium‑ to long‑term forecasts: FY2028 estimate improved (from -$0.85 to -$0.54), FY2029 was materially upgraded (from -$0.07 to +$1.79), and HCW now projects FY2030 at +$4.38 — these changes suggest the analyst sees a path to profitability in later years, supporting speculative, growth‑oriented investor demand. HC Wainwright Long‑Term Estimate Changes
• Negative Sentiment: HC Wainwright materially lowered near‑term EPS: Q1–Q4 2026 and FY2026 estimates were cut (Q1 to -$0.77 from -$0.55; Q2 to -$0.82 from -$0.58; Q3 to -$0.91 from -$0.65; Q4 to -$1.02 from -$0.73; FY2026 to -$3.53 from -$2.52). The sharp downgrade to FY2026 EPS reduces near‑term earnings visibility and increases short‑term risk. HC Wainwright Near‑Term Cuts

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.